104 results
Page 4 of 6
F-3
r8vxzd7
20 May 22
Shelf registration (foreign)
5:22pm
6-K
EX-99.1
hhlo7zh v4d
12 May 22
Current report (foreign)
4:35pm
6-K
EX-99.2
krykp
12 May 22
Current report (foreign)
4:35pm
6-K
EX-99.1
xti1 wi29wt
11 May 22
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
7:30am
6-K
EX-99.1
oxszhg9ps2ixvg
10 May 22
Current report (foreign)
5:25pm
6-K
EX-99.1
oozk bjwo
22 Mar 22
Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
6:30am
6-K
EX-99.1
ogc5 vaiyb8syd9etz
15 Mar 22
Evaxion Biotech Strengthens Management Team with Two Senior Appointments
9:26am
6-K
EX-99.1
qbeyi0mhnra1ob og
7 Mar 22
Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02
4:17pm
6-K
EX-99.1
vuwm4
18 Jan 22
Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma
4:30pm
6-K
EX-99.2
jrn g1ni8
10 Nov 21
Current report (foreign)
4:40pm
6-K
EX-99.1
gn02q8ryur3p tomrm
10 Nov 21
Current report (foreign)
4:40pm
6-K
EX-99.1
esy84of5
9 Nov 21
Current report (foreign)
5:00pm
6-K
EX-99.1
oept3sqzmma
9 Nov 21
Evaxion Biotech Announces Q3 2021 Financial Results and Provides Business Update
6:29am
424B4
zs2mb0c38d8x3fprui
5 Nov 21
Prospectus supplement with pricing info
4:47pm
6-K
EX-99.1
rpk5tu8f0
5 Nov 21
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
8:30am
F-1/A
40zrn4yni7 nysvgfj5p
3 Nov 21
Registration statement (foreign) (amended)
7:50am
6-K
EX-99.1
bzdq 9iyn6g3
27 Oct 21
Evaxion Biotech Announces Filing of Registration Statement in the U.S for Proposed Follow-on Public Offering to Raise Additional Capital
4:29pm
F-1
lg4j2ddggv85qdqh0j
26 Oct 21
Registration statement (foreign)
7:02am
6-K
EX-99.1
locpkcv0
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am